- [Home](/) › - [ClinicalTrialStartPulse](/v/clinicaltrialstartpulse) › - [Hubs](/hub/clinicaltrialstartpulse) › - [All record reports](/hub/clinicaltrialstartpulse/records) › - Page 4 # ClinicalTrialStartPulse: all 1,000 record reports, page 4 of 5 Every ClinicalTrialStartPulse record report, 200 per page, grouped by state. Records 601 to 800: University of Geneva, Switzerland: Observational study in Sepsis, Long Term Care (530 participants) to Janssen Research & Development, LLC: Phase 2 study started recruiting, 440 planned (Asthma). Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2. [1](/hub/clinicaltrialstartpulse/records) [2](/hub/clinicaltrialstartpulse/records/2) [3](/hub/clinicaltrialstartpulse/records/3) 4 [5](/hub/clinicaltrialstartpulse/records/5) ## NONUS - [University of Geneva, Switzerland: Observational study in Sepsis, Long Term Care (530 participants)](/report/clinicaltrialstartpulse/university-of-geneva-switzerland-nonus--nct-nct07863128) - [University of Helsinki: Not applicable (device, behavioral) study in Learning, Comprehensive Wellbeing (1440 participants)](/report/clinicaltrialstartpulse/university-of-helsinki-nonus--nct-nct07906522) - [University of Jordan: Early phase 1 study in Benign Paroxismal Positional Vertigo (404 participants)](/report/clinicaltrialstartpulse/university-of-jordan-nonus--nct-nct07861464) - [University of Karachi: Not applicable (device, behavioral) study in Focus of the Study is Smoking Cessation and Prevention, Smoking Prevention (600 participants)](/report/clinicaltrialstartpulse/university-of-karachi-nonus--nct-nct07895784) - [University of L'Aquila: Observational study in Stroke, Malignancies Multiple (1000 participants)](/report/clinicaltrialstartpulse/university-of-l-aquila-nonus--nct-nct07895173) - [University of Latvia: Observational study in Helicobacter Pylori Infection, Colorectal Cancer (8000 participants)](/report/clinicaltrialstartpulse/university-of-latvia-nonus--nct-nct07873580) - [University of Malaya: Phase 2 study in Type 2 Diabetes Mellitus (DM) (360 participants)](/report/clinicaltrialstartpulse/university-of-malaya-nonus--nct-nct07888426) - [University of Medicine and Pharmacy at Ho Chi Minh City: Not applicable (device, behavioral) study in Depression - Major Depressive Disorder (550 participants)](/report/clinicaltrialstartpulse/university-of-medicine-and-pharmacy-at-ho-chi-minh-city-nonus--nct-nct07877571) - [University of Minnesota: Not applicable (device, behavioral) study closed enrollment, 312 enrolled (Health Knowledge, Attitudes, Practice, Training)](/report/clinicaltrialstartpulse/university-of-minnesota-nonus--nct-nct06428058-enrollment) - [University of Minnesota: Observational study closed enrollment, 21680 enrolled (Cardiovascular Diseases, Pulmonary Embolism)](/report/clinicaltrialstartpulse/university-of-minnesota-nonus--nct-nct00005504-enrollment) - [University of Monastir: Observational study in Adherence, Medication (3000 participants)](/report/clinicaltrialstartpulse/university-of-monastir-nonus--nct-nct07864532) - [University of Monastir: Observational study in Lower Extremity Injuries, Venous Thromboembolism (VTE) (1500 participants)](/report/clinicaltrialstartpulse/university-of-monastir-nonus--nct-nct07863115) - [University of North Carolina, Chapel Hill: Not applicable (device, behavioral) study closed enrollment, 3234 enrolled (HIV-1-infection, Unhealthy Alcohol Use)](/report/clinicaltrialstartpulse/university-of-north-carolina-chapel-hill-nonus--nct-nct06358885-enrollment) - [University of North Carolina, Chapel Hill: Not applicable (device, behavioral) study in Malaria (Plasmodium Falciparum), Malaria Incidence (1350 participants)](/report/clinicaltrialstartpulse/university-of-north-carolina-chapel-hill-nonus--nct-nct07903324) - [University of Novi Sad: Not applicable (device, behavioral) study in Postural Alignment, Posture (398 participants)](/report/clinicaltrialstartpulse/university-of-novi-sad-nonus--nct-nct07886749) - [University of Oulu: Not applicable (device, behavioral) study in Acute Low Back Pain (Low Back Pain for Less Than 3 Months) (461 participants)](/report/clinicaltrialstartpulse/university-of-oulu-nonus--nct-nct07877454) - [University of Oxford: Observational study in Spinal Muscular Atrophy (SMA) (750000 participants)](/report/clinicaltrialstartpulse/university-of-oxford-nonus--nct-nct07888868) - [University of Oxford: Phase 2 study completed, 390 enrolled (Malaria,Falciparum)](/report/clinicaltrialstartpulse/university-of-oxford-nonus--nct-nct05790889-completed) - [University of Salford: Observational study completed, 1161 enrolled (Rhabdomyolysis, Death)](/report/clinicaltrialstartpulse/university-of-salford-nonus--nct-nct07158554-completed) - [University of Sao Paulo General Hospital: Phase 4 study started recruiting, 352 planned (Autoimmune Rheumatic Diseases, Tooth Extraction)](/report/clinicaltrialstartpulse/university-of-sao-paulo-general-hospital-nonus--nct-nct07275580-recruiting) - [University of Sao Paulo: Observational study in Sudden Cardiac Death, Cardiac Arrhythmias (334 participants)](/report/clinicaltrialstartpulse/university-of-sao-paulo-nonus--nct-nct07862504) - [University of Southern Denmark: Observational study in Tobacco Use Behavior, Nicotine Dependence Tobacco Product (10000 participants)](/report/clinicaltrialstartpulse/university-of-southern-denmark-nonus--nct-nct07910331) - [University of Texas Southwestern Medical Center: Observational study in Cancer, Malignant Neoplasm (10000 participants)](/report/clinicaltrialstartpulse/university-of-texas-southwestern-medical-center-nonus--nct-nct07886853) - [University of Ulm: Not applicable (device, behavioral) study closed enrollment, 399 enrolled (Amyotrophic Lateral Sclerosis)](/report/clinicaltrialstartpulse/university-of-ulm-nonus--nct-nct06280079-enrollment) - [University of Washington: Not applicable (device, behavioral) study in Breast Cancer (873 participants)](/report/clinicaltrialstartpulse/university-of-washington-nonus--nct-nct07858825) - [University of Washington: Not applicable (device, behavioral) study in Hearing Loss, Bilateral or Unilateral, Otitis Media With Effusion in Children (400 participants)](/report/clinicaltrialstartpulse/university-of-washington-nonus--nct-nct07879326) - [University of Wisconsin, Madison: Not applicable (device, behavioral) study closed enrollment, 449 enrolled (Hypertension)](/report/clinicaltrialstartpulse/university-of-wisconsin-madison-nonus--nct-nct06444308-enrollment) - [University of Yalova: Observational study in Education Nursing (346 participants)](/report/clinicaltrialstartpulse/university-of-yalova-nonus--nct-nct07894731) - [University of Zurich: Observational study in Postpartum Hemorrhage, Treatment Outcome (380 participants)](/report/clinicaltrialstartpulse/university-of-zurich-nonus--nct-nct07885072) - [VASCage GmbH: Observational study in Chronic Obstructive Pulmonary Disease (COPD), Severe Asthma (350 participants)](/report/clinicaltrialstartpulse/vascage-gmbh-nonus--nct-nct07856667) - [Vejle Hospital: Observational study started recruiting, 400 planned (Subacromial Pain Syndrome, Rotator Cuff Related Shoulder Pain)](/report/clinicaltrialstartpulse/vejle-hospital-nonus--nct-nct07792434-recruiting) - [Vestre Viken Hospital Trust: Phase 4 study in Coronary Arterial Disease (CAD) (7000 participants)](/report/clinicaltrialstartpulse/vestre-viken-hospital-trust-nonus--nct-nct07854795) - [Vietnam Military Medical University: Not applicable (device, behavioral) study started recruiting, 380 planned (Infertility (IVF Patients), Infertility Assisted Reproductive Technology)](/report/clinicaltrialstartpulse/vietnam-military-medical-university-nonus--nct-nct07772375-recruiting) - [Viking Therapeutics, Inc.: Phase 3 study in Weight Loss (560 participants)](/report/clinicaltrialstartpulse/viking-therapeutics-inc-nonus--nct-nct07868939) - [Viking Therapeutics, Inc.: Phase 3 study in Weight Loss (560 participants)](/report/clinicaltrialstartpulse/viking-therapeutics-inc-nonus--nct-nct07868835) - [Washington University School of Medicine: Not applicable (device, behavioral) study completed, 1515 enrolled (Moderate Acute Malnutrition)](/report/clinicaltrialstartpulse/washington-university-school-of-medicine-nonus--nct-nct06214897-completed) - [Washington University School of Medicine: Not applicable (device, behavioral) study in HIV, HIV - Human Immunodeficiency Virus (1500 participants)](/report/clinicaltrialstartpulse/washington-university-school-of-medicine-nonus--nct-nct07900750) - [Wellbeing Services County of Pirkanmaa: Not applicable (device, behavioral) study started recruiting, 600 planned (Hypertension)](/report/clinicaltrialstartpulse/wellbeing-services-county-of-pirkanmaa-nonus--nct-nct07812350-recruiting) - [West China Hospital: Observational study in Liver Metastases, Gastric Adenocarcinoma (700 participants)](/report/clinicaltrialstartpulse/west-china-hospital-nonus--nct-nct07871019) - [West China Hospital: Observational study in Resectable Hepatocellular Carcinoma (HCC) (380 participants)](/report/clinicaltrialstartpulse/west-china-hospital-nonus--nct-nct07912853) - [West China Hospital: Phase 3 study in Non-small Cell Lung Cancer (NSCLC) (1088 participants)](/report/clinicaltrialstartpulse/west-china-hospital-nonus--nct-nct07895238) - [Wockhardt: Phase 3 study in Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP) (324 participants)](/report/clinicaltrialstartpulse/wockhardt-nonus--nct-nct07885891) - [Women's Cancer Study Group GmbH: Phase 3 study closed enrollment, 1684 enrolled (Breast Cancer Female)](/report/clinicaltrialstartpulse/women-s-cancer-study-group-gmbh-nonus--nct-nct04055493-enrollment) - [Women's Hospital School Of Medicine Zhejiang University: Observational study in Pregnancy Complicated With Intrauterine Adhesion (360 participants)](/report/clinicaltrialstartpulse/women-s-hospital-school-of-medicine-zhejiang-university-nonus--nct-nct07883057) - [Wonju Severance Christian Hospital: Not applicable (device, behavioral) study in Gynecologic Surgery, General Anesthesia (350 participants)](/report/clinicaltrialstartpulse/wonju-severance-christian-hospital-nonus--nct-nct07868952) - [World Vision US: Observational study in Child Malnutrition, Wasting Syndrome (571 participants)](/report/clinicaltrialstartpulse/world-vision-us-nonus--nct-nct07906067) - [Xiangya Hospital of Central South University: Not applicable (device, behavioral) study in Type 2 Diabetes Mellitus (15400 participants)](/report/clinicaltrialstartpulse/xiangya-hospital-of-central-south-university-nonus--nct-nct07885904) - [Xuanwu Hospital, Beijing: Not applicable (device, behavioral) study in Acute Ischemic Stroke (1200 participants)](/report/clinicaltrialstartpulse/xuanwu-hospital-beijing-nonus--nct-nct07882030) - [Xuanwu Hospital, Beijing: Not applicable (device, behavioral) study in Acute Ischemic Stroke (320 participants)](/report/clinicaltrialstartpulse/xuanwu-hospital-beijing-nonus--nct-nct07892053) - [Xuanwu Hospital, Beijing: Observational study in Mild Cognitive Impairment (MCI) (600 participants)](/report/clinicaltrialstartpulse/xuanwu-hospital-beijing-nonus--nct-nct07876570) - [Yonsei University: Observational study in Coronary Artery Disease (600 participants)](/report/clinicaltrialstartpulse/yonsei-university-nonus--nct-nct07869602) - [Yonsei University: Observational study in Neurodegenerative Disease, Mild Cognitive Impairmen (1550 participants)](/report/clinicaltrialstartpulse/yonsei-university-nonus--nct-nct07880275) - [Yonsei University: Observational study in Patients Undergoing Valvular Heart Surgery (4230 participants)](/report/clinicaltrialstartpulse/yonsei-university-nonus--nct-nct07907198) - [Yonsei University: Phase 4 study in Nonobstructive Hypertrophic Cardiomyopathy (440 participants)](/report/clinicaltrialstartpulse/yonsei-university-nonus--nct-nct07897500) - [Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.: Phase 3 study in Diabetic Peripheral Neuropathic Pain (DPNP) (400 participants)](/report/clinicaltrialstartpulse/zhejiang-hanmai-pharmaceutical-technology-co-ltd-nonus--nct-nct07859111) - [Zhejiang Hospital: Not applicable (device, behavioral) study in Coronary Artery Disease (554 participants)](/report/clinicaltrialstartpulse/zhejiang-hospital-nonus--nct-nct07855614) - [Zhejiang Hospital: Observational study in Coronary Artery Disease (326 participants)](/report/clinicaltrialstartpulse/zhejiang-hospital-nonus--nct-nct07886996) - [Zhongnan Hospital: Observational study in PICC-associated Thrombosis (1655 participants)](/report/clinicaltrialstartpulse/zhongnan-hospital-nonus--nct-nct07906912) - [Zhongshan Ophthalmic Center, Sun Yat-sen University: Not applicable (device, behavioral) study in Refractive Errors (508 participants)](/report/clinicaltrialstartpulse/zhongshan-ophthalmic-center-sun-yat-sen-university-nonus--nct-nct07891897) - [Zhongshan Ophthalmic Center, Sun Yat-sen University: Not applicable (device, behavioral) study in Systemic Health Risk (2000 participants)](/report/clinicaltrialstartpulse/zhongshan-ophthalmic-center-sun-yat-sen-university-nonus--nct-nct07890922) ## US - [4D Molecular Therapeutics: Phase 3 study in Diabetic Macular Edema (DME) (514 participants)](/report/clinicaltrialstartpulse/4d-molecular-therapeutics-us--nct-nct07867080) - [Abbott Point of Care: Observational study in Lactate (425 participants)](/report/clinicaltrialstartpulse/abbott-point-of-care-us--nct-nct07908056) - [AbbVie: Observational study completed, 8250 enrolled (Ulcerative Colitis (UC))](/report/clinicaltrialstartpulse/abbvie-us--nct-nct01848561-completed) - [AbbVie: Phase 3 study closed enrollment, 2701 enrolled (Hypothyroidism)](/report/clinicaltrialstartpulse/abbvie-us--nct-nct06345339-enrollment) - [AbbVie: Phase 3 study closed enrollment, 699 enrolled (Atopic Dermatitis)](/report/clinicaltrialstartpulse/abbvie-us--nct-nct06461897-enrollment) - [Abramson Cancer Center at Penn Medicine: Not applicable (device, behavioral) study in Genetic Predisposition to Cancer (1000 participants)](/report/clinicaltrialstartpulse/abramson-cancer-center-at-penn-medicine-us--nct-nct07911592) - [Accelerated Cure Project for Multiple Sclerosis: Observational study closed enrollment, 3226 enrolled (Multiple Sclerosis, Transverse Myelitis)](/report/clinicaltrialstartpulse/accelerated-cure-project-for-multiple-sclerosis-us--nct-nct00445367-enrollment) - [AcQumen Medical, Inc.: Observational study in Hemodynamic Monitoring (400 participants)](/report/clinicaltrialstartpulse/acqumen-medical-inc-us--nct-nct07862608) - [Active Genomes Expressed Diagnostics, Corp: Observational study in MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) (500 participants)](/report/clinicaltrialstartpulse/active-genomes-expressed-diagnostics-corp-us--nct-nct07867574) - [Agios Pharmaceuticals, Inc.: Observational study closed enrollment, 500 enrolled (Pyruvate Kinase Deficiency)](/report/clinicaltrialstartpulse/agios-pharmaceuticals-inc-us--nct-nct03481738-enrollment) - [AI Agent Vault, Inc. d/b/a Precision Mito: Observational study in Mitochondrial Diseases, Myalgic Encephalomyelitis Chronic Fatigue Syndrome (400 participants)](/report/clinicaltrialstartpulse/ai-agent-vault-inc-d-b-a-precision-mito-us--nct-nct07856121) - [Alexion Pharmaceuticals, Inc.: Phase 3 study closed enrollment, 1182 enrolled (Transthyretin Amyloid Cardiomyopathy)](/report/clinicaltrialstartpulse/alexion-pharmaceuticals-inc-us--nct-nct06183931-enrollment) - [Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute): Not applicable (device, behavioral) study in Atrial Fibrillation (AF) (334 participants)](/report/clinicaltrialstartpulse/allegheny-singer-research-institute-also-known-as-allegheny-us--nct-nct07874763) - [Alliance for Clinical Trials in Oncology: Phase 3 study closed enrollment, 1167 enrolled (Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8)](/report/clinicaltrialstartpulse/alliance-for-clinical-trials-in-oncology-us--nct-nct04379570-enrollment) - [Alpha-1 Foundation: Observational study in Alpha-1 Antitrypsin Deficiency, AATD (1000 participants)](/report/clinicaltrialstartpulse/alpha-1-foundation-us--nct-nct07898553) - [American College of Cardiology: Observational study in Aortic Valve Stenosis (50000 participants)](/report/clinicaltrialstartpulse/american-college-of-cardiology-us--nct-nct07908355) - [Amgen: Phase 3 study closed enrollment, 7297 enrolled (Atherosclerotic Cardiovascular Disease)](/report/clinicaltrialstartpulse/amgen-us--nct-nct05581303-enrollment) - [Andreas NLP (Legal Entity - Real People Press): Not applicable (device, behavioral) study in Psychological Distress, Psychological Well-being (480 participants)](/report/clinicaltrialstartpulse/andreas-nlp-legal-entity-real-people-press-us--nct-nct07879196) - [Annexon, Inc.: Phase 3 study closed enrollment, 659 enrolled (Geographic Atrophy)](/report/clinicaltrialstartpulse/annexon-inc-us--nct-nct06510816-enrollment) - [Apogee Therapeutics, Inc.: Phase 2 study closed enrollment, 470 enrolled (Atopic Dermatitis)](/report/clinicaltrialstartpulse/apogee-therapeutics-inc-us--nct-nct06395948-enrollment) - [Apple Inc.: Observational study terminated, 268037 enrolled (Hearing Loss, Noise-Induced, Hearing Loss)](/report/clinicaltrialstartpulse/apple-inc-us--nct-nct04172766-terminated) - [Aragon Pharmaceuticals, Inc.: Phase 3 study closed enrollment, 1503 enrolled (Prostatic Neoplasms)](/report/clinicaltrialstartpulse/aragon-pharmaceuticals-inc-us--nct-nct02531516-enrollment) - [ArriVent BioPharma, Inc.: Phase 3 study closed enrollment, 398 enrolled (Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer)](/report/clinicaltrialstartpulse/arrivent-biopharma-inc-us--nct-nct05607550-enrollment) - [Ascendis Pharma Oncology Division A/S: Phase 2 study closed enrollment, 320 enrolled (Advanced Solid Tumor, Locally Advanced Solid Tumor)](/report/clinicaltrialstartpulse/ascendis-pharma-oncology-division-a-s-us--nct-nct05081609-enrollment) - [Astellas Pharma Global Development, Inc.: Observational study closed enrollment, 488 enrolled (Geographic Atrophy, Macular Degeneration)](/report/clinicaltrialstartpulse/astellas-pharma-global-development-inc-us--nct-nct06779773-enrollment) - [Astellas Pharma Global Development, Inc.: Phase 2 study closed enrollment, 393 enrolled (Pancreatic Cancer, Metastatic Pancreatic Cancer)](/report/clinicaltrialstartpulse/astellas-pharma-global-development-inc-us--nct-nct03816163-enrollment) - [AstraZeneca: Observational study completed, 8681 enrolled (Asthma)](/report/clinicaltrialstartpulse/astrazeneca-us--nct-nct07787117-completed) - [AstraZeneca: Phase 2 study closed enrollment, 477 enrolled (Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorecta](/report/clinicaltrialstartpulse/astrazeneca-us--nct-nct04482309-enrollment) - [AstraZeneca: Phase 3 study closed enrollment, 1157 enrolled (Breast Cancer, HER2-positive)](/report/clinicaltrialstartpulse/astrazeneca-us--nct-nct04784715-enrollment) - [AstraZeneca: Phase 3 study closed enrollment, 1174 enrolled (Breast Cancer)](/report/clinicaltrialstartpulse/astrazeneca-us--nct-nct05629585-enrollment) - [AstraZeneca: Phase 3 study closed enrollment, 1350 enrolled (NSCLC)](/report/clinicaltrialstartpulse/astrazeneca-us--nct-nct05687266-enrollment) - [AstraZeneca: Phase 3 study closed enrollment, 1835 enrolled (Chronic Kidney Disease With High Proteinuria)](/report/clinicaltrialstartpulse/astrazeneca-us--nct-nct06087835-enrollment) - [AstraZeneca: Phase 3 study closed enrollment, 1902 enrolled (Breast Cancer)](/report/clinicaltrialstartpulse/astrazeneca-us--nct-nct06112379-enrollment) - [AstraZeneca: Phase 3 study closed enrollment, 363 enrolled (Lupus Nephritis)](/report/clinicaltrialstartpulse/astrazeneca-us--nct-nct05138133-enrollment) - [AstraZeneca: Phase 3 study closed enrollment, 640 enrolled (Esophageal Squamous Cell Carcinoma)](/report/clinicaltrialstartpulse/astrazeneca-us--nct-nct04550260-enrollment) - [AstraZeneca: Phase 3 study closed enrollment, 760 enrolled (Biliary Tract Cancer)](/report/clinicaltrialstartpulse/astrazeneca-us--nct-nct06109779-enrollment) - [AstraZeneca: Phase 3 study closed enrollment, 768 enrolled (Metastatic Non-small Cell Lung Cancer)](/report/clinicaltrialstartpulse/astrazeneca-us--nct-nct06417814-enrollment) - [AstraZeneca: Phase 3 study closed enrollment, 863 enrolled (Unresectable Pleural Mesothelioma)](/report/clinicaltrialstartpulse/astrazeneca-us--nct-nct06097728-enrollment) - [AstraZeneca: Phase 3 study started recruiting, 1330 planned (Metastatic Hormone-Sensitive Prostate Cancer (mHSPC))](/report/clinicaltrialstartpulse/astrazeneca-us--nct-nct07711002-recruiting) - [AstraZeneca: Phase 3 study started recruiting, 600 planned (Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer)](/report/clinicaltrialstartpulse/astrazeneca-us--nct-nct07816666-recruiting) - [AstraZeneca: Phase 3 study started recruiting, 750 planned (Newly Diagnosed Multiple Myeloma (NDMM))](/report/clinicaltrialstartpulse/astrazeneca-us--nct-nct07735637-recruiting) - [Avalyn Pharma Inc.: Phase 2 study closed enrollment, 398 enrolled (Pulmonary Fibrosis, Progressive Pulmonary Fibrosis)](/report/clinicaltrialstartpulse/avalyn-pharma-inc-us--nct-nct06329401-enrollment) - [Azienda Unità Sanitaria Locale della Romagna: Observational study completed, 4230 enrolled (Acute Ischemic Stroke Related to Tandem Occlusion, Acute Ischemic Stroke Due to Isolated Cervical Artery Occlusion)](/report/clinicaltrialstartpulse/azienda-unita-sanitaria-locale-della-romagna-us--nct-nct06965036-completed) - [Bactolife A/S: Not applicable (device, behavioral) study in Gut Health, Gastrointestinal Symptoms (800 participants)](/report/clinicaltrialstartpulse/bactolife-a-s-us--nct-nct07873957) - [Baptist Health South Florida: Not applicable (device, behavioral) study completed, 335 enrolled (Perceptions of Caring, Hospital Readmissions)](/report/clinicaltrialstartpulse/baptist-health-south-florida-us--nct-nct07136350-completed) - [Bayer: Observational study closed enrollment, 4613 enrolled (Chronic Kidney Disease, Type 2 Diabetes Mellitus)](/report/clinicaltrialstartpulse/bayer-us--nct-nct05348733-enrollment) - [Baylor Research Institute: Observational study in Surgical Site Infection, Vaginal Cuff Cellulitis (900 participants)](/report/clinicaltrialstartpulse/baylor-research-institute-us--nct-nct07888101) - [Beeline Medicines Corporation: Phase 3 study in Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus (390 participants)](/report/clinicaltrialstartpulse/beeline-medicines-corporation-us--nct-nct07881120) - [BeiGene: Phase 2 study completed, 418 enrolled (Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer)](/report/clinicaltrialstartpulse/beigene-us--nct-nct05635708-completed) - [BeOne Medicines: Phase 3 study closed enrollment, 799 enrolled (Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma)](/report/clinicaltrialstartpulse/beone-medicines-us--nct-nct05100862-enrollment) - [BioNTech SE: Phase 1 study closed enrollment, 318 enrolled (Genital Herpes Simplex Type 2)](/report/clinicaltrialstartpulse/biontech-se-us--nct-nct05432583-enrollment) - [BioNTech SE: Phase 3 study closed enrollment, 358 enrolled (Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer)](/report/clinicaltrialstartpulse/biontech-se-us--nct-nct04534205-enrollment) - [BioNTech SE: Phase 3 study completed, 5240 enrolled (COVID-19, SARS-COV-2 Infection)](/report/clinicaltrialstartpulse/biontech-se-us--nct-nct07300839-completed) - [Bladder Cancer Advocacy Network: Observational study in NMIBC, MIBC (1400 participants)](/report/clinicaltrialstartpulse/bladder-cancer-advocacy-network-us--nct-nct07893509) - [Boston Medical Center: Not applicable (device, behavioral) study closed enrollment, 600 enrolled (Parent-Child Relations, Parenting)](/report/clinicaltrialstartpulse/boston-medical-center-us--nct-nct03641092-enrollment) - [Boston Scientific Corporation: Not applicable (device, behavioral) study closed enrollment, 3000 enrolled (Atrial Fibrillation, Stroke)](/report/clinicaltrialstartpulse/boston-scientific-corporation-us--nct-nct04394546-enrollment) - [Boston Scientific Corporation: Not applicable (device, behavioral) study closed enrollment, 500 enrolled (Prostate Cancer)](/report/clinicaltrialstartpulse/boston-scientific-corporation-us--nct-nct04905069-enrollment) - [Boston Scientific Corporation: Not applicable (device, behavioral) study started recruiting, 400 planned (Atrial Fibrillation (AF), Stroke)](/report/clinicaltrialstartpulse/boston-scientific-corporation-us--nct-nct07287436-recruiting) - [Brigham and Women's Hospital: Not applicable (device, behavioral) study closed enrollment, 640 enrolled (Genetic Predisposition to Disease, Hereditary Diseases)](/report/clinicaltrialstartpulse/brigham-and-women-s-hospital-us--nct-nct05161169-enrollment) - [Brigham and Women's Hospital: Observational study closed enrollment, 10718 enrolled (Pulmonary Disease, Chronic Obstructive, Emphysema)](/report/clinicaltrialstartpulse/brigham-and-women-s-hospital-us--nct-nct00608764-enrollment) - [Brigham and Women's Hospital: Observational study in Metastatic Colorectal Cancer (mCRC) (1030 participants)](/report/clinicaltrialstartpulse/brigham-and-women-s-hospital-us--nct-nct07861347) - [Brigham and Women's Hospital: Observational study in Metastatic Colorectal Cancer (mCRC) (400 participants)](/report/clinicaltrialstartpulse/brigham-and-women-s-hospital-us--nct-nct07861360) - [Brigham and Women's Hospital: Observational study in Metastatic Colorectal Cancer (mCRC) (9978 participants)](/report/clinicaltrialstartpulse/brigham-and-women-s-hospital-us--nct-nct07861386) - [Bristol-Myers Squibb: Phase 3 study completed, 1314 enrolled (Urothelial Cancer)](/report/clinicaltrialstartpulse/bristol-myers-squibb-us--nct-nct03036098-completed) - [Brown University: Not applicable (device, behavioral) study closed enrollment, 2300 enrolled (Healthy)](/report/clinicaltrialstartpulse/brown-university-us--nct-nct05357261-enrollment) - [Calyxo, Inc.: Observational study started recruiting, 1000 planned (Urolithiasis, Stones, Kidney)](/report/clinicaltrialstartpulse/calyxo-inc-us--nct-nct07155005-recruiting) - [Cardiology Consultants of Philadelphia: Observational study in ASCVD (2500 participants)](/report/clinicaltrialstartpulse/cardiology-consultants-of-philadelphia-us--nct-nct07883564) - [Carmot Therapeutics, Inc.: Phase 2 study completed, 447 enrolled (Overweight or Obese, Type 2 Diabetes Mellitus (T2DM))](/report/clinicaltrialstartpulse/carmot-therapeutics-inc-us--nct-nct06628362-completed) - [Chestnut Health Systems: Phase 3 study in Substance Use Disorder (SUD), Opioid Use Disorders (600 participants)](/report/clinicaltrialstartpulse/chestnut-health-systems-us--nct-nct07873944) - [Children's Hospital Medical Center, Cincinnati: Not applicable (device, behavioral) study closed enrollment, 787 enrolled (Genetic Screening, Adolescent)](/report/clinicaltrialstartpulse/children-s-hospital-medical-center-cincinnati-us--nct-nct04481061-enrollment) - [Children's Hospital Medical Center, Cincinnati: Observational study completed, 1102 enrolled (Depression Disorders, Suicidality)](/report/clinicaltrialstartpulse/children-s-hospital-medical-center-cincinnati-us--nct-nct06979479-completed) - [Children's Hospital of Philadelphia: Not applicable (device, behavioral) study in Postpartum Complication, Postpartum (640 participants)](/report/clinicaltrialstartpulse/children-s-hospital-of-philadelphia-us--nct-nct07881731) - [Children's Hospital of Philadelphia: Not applicable (device, behavioral) study in Postpartum, Postpartum Depression (PPD) (756 participants)](/report/clinicaltrialstartpulse/children-s-hospital-of-philadelphia-us--nct-nct07873190) - [Children's Hospital of Philadelphia: Observational study in Cardiac Arrest (CA) (1620 participants)](/report/clinicaltrialstartpulse/children-s-hospital-of-philadelphia-us--nct-nct07890610) - [Children's Oncology Group: Phase 3 study closed enrollment, 391 enrolled (Ganglioneuroblastoma, Localized Resectable Neuroblastoma)](/report/clinicaltrialstartpulse/children-s-oncology-group-us--nct-nct02176967-enrollment) - [City of Hope Medical Center: Not applicable (device, behavioral) study closed enrollment, 1062 enrolled (Cognitive/Functional Effects, Psychosocial Effects of Cancer and Its Treatment)](/report/clinicaltrialstartpulse/city-of-hope-medical-center-us--nct-nct00477958-enrollment) - [City of Hope Medical Center: Not applicable (device, behavioral) study closed enrollment, 344 enrolled (Healthy Subject)](/report/clinicaltrialstartpulse/city-of-hope-medical-center-us--nct-nct03303846-enrollment) - [City of Hope Medical Center: Observational study started recruiting, 423 planned (Breast Carcinoma)](/report/clinicaltrialstartpulse/city-of-hope-medical-center-us--nct-nct07690852-recruiting) - [Columbia University: Not applicable (device, behavioral) study closed enrollment, 23928 enrolled (Hypertension)](/report/clinicaltrialstartpulse/columbia-university-us--nct-nct05885997-enrollment) - [Columbia University: Not applicable (device, behavioral) study closed enrollment, 749 enrolled (Glaucoma, Vision Impairment and Blindness)](/report/clinicaltrialstartpulse/columbia-university-us--nct-nct04271709-enrollment) - [Columbia University: Phase 3 study started recruiting, 1010 planned (Abdominal Pain, Isolated Extremity Fracture)](/report/clinicaltrialstartpulse/columbia-university-us--nct-nct06835504-recruiting) - [Connecticut Children's Medical Center: Phase 4 study closed enrollment, 1270 enrolled (Crohn Disease)](/report/clinicaltrialstartpulse/connecticut-children-s-medical-center-us--nct-nct05781152-enrollment) - [CorDx, Inc.: Not applicable (device, behavioral) study in SARS-CoV-2 Infection, Influenza A (1500 participants)](/report/clinicaltrialstartpulse/cordx-inc-us--nct-nct07875270) - [Dana-Farber Cancer Institute: Phase 2 study closed enrollment, 393 enrolled (HER2-positive Breast Cancer, Invasive Carcinoma of the Breast)](/report/clinicaltrialstartpulse/dana-farber-cancer-institute-us--nct-nct04569747-enrollment) - [Day One Biopharmaceuticals, Inc.: Phase 3 study closed enrollment, 418 enrolled (Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma)](/report/clinicaltrialstartpulse/day-one-biopharmaceuticals-inc-us--nct-nct05566795-enrollment) - [Deepull Diagnostics S.L.: Observational study in Blood Stream Infection, Blood Stream Infections (1500 participants)](/report/clinicaltrialstartpulse/deepull-diagnostics-s-l-us--nct-nct07859852) - [DePuy International: Not applicable (device, behavioral) study closed enrollment, 1542 enrolled (Noninflammatory Degenerative Joint Disease)](/report/clinicaltrialstartpulse/depuy-international-us--nct-nct01754363-enrollment) - [DePuy Orthopaedics: Not applicable (device, behavioral) study closed enrollment, 400 enrolled (Primary Knee Arthroplasty)](/report/clinicaltrialstartpulse/depuy-orthopaedics-us--nct-nct03153449-enrollment) - [DePuy Orthopaedics: Not applicable (device, behavioral) study closed enrollment, 400 enrolled (Revision Total Knee Arthroplasty)](/report/clinicaltrialstartpulse/depuy-orthopaedics-us--nct-nct03153475-enrollment) - [dfusion Inc: Not applicable (device, behavioral) study in Education, Sex (365 participants)](/report/clinicaltrialstartpulse/dfusion-inc-us--nct-nct07880912) - [dōTERRA International: Not applicable (device, behavioral) study completed, 313 enrolled (Healthy)](/report/clinicaltrialstartpulse/doterra-international-us--nct-nct07623811-completed) - [Duke University: Not applicable (device, behavioral) study completed, 1800 enrolled (Pain, Back)](/report/clinicaltrialstartpulse/duke-university-us--nct-nct05626049-completed) - [Eastern Cooperative Oncology Group: Phase 3 study closed enrollment, 540 enrolled (Brain and Central Nervous System Tumors, Neurotoxicity)](/report/clinicaltrialstartpulse/eastern-cooperative-oncology-group-us--nct-nct00978458-enrollment) - [ECOG-ACRIN Cancer Research Group: Phase 2 study closed enrollment, 2175 enrolled (Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8)](/report/clinicaltrialstartpulse/ecog-acrin-cancer-research-group-us--nct-nct04266249-enrollment) - [ECOG-ACRIN Cancer Research Group: Phase 3 study closed enrollment, 1087 enrolled (Plasma Cell Myeloma)](/report/clinicaltrialstartpulse/ecog-acrin-cancer-research-group-us--nct-nct01863550-enrollment) - [Eisai Inc.: Phase 3 study closed enrollment, 1906 enrolled (Early Alzheimer's Disease)](/report/clinicaltrialstartpulse/eisai-inc-us--nct-nct03887455-enrollment) - [Eli Lilly and Company: Phase 1 study in Obesity, Overweight (617 participants)](/report/clinicaltrialstartpulse/eli-lilly-and-company-us--nct-nct07881887) - [Eli Lilly and Company: Phase 2 study in Obesity, Overweight (460 participants)](/report/clinicaltrialstartpulse/eli-lilly-and-company-us--nct-nct07890376) - [Eli Lilly and Company: Phase 3 study closed enrollment, 15374 enrolled (Obesity, Overweight)](/report/clinicaltrialstartpulse/eli-lilly-and-company-us--nct-nct05556512-enrollment) - [Eli Lilly and Company: Phase 3 study in Obesity (2115 participants)](/report/clinicaltrialstartpulse/eli-lilly-and-company-us--nct-nct07881432) - [Eli Lilly and Company: Phase 3 study in Obesity, Overweight (1000 participants)](/report/clinicaltrialstartpulse/eli-lilly-and-company-us--nct-nct07881458) - [Eli Lilly and Company: Phase 3 study in Obesity, Overweight (3000 participants)](/report/clinicaltrialstartpulse/eli-lilly-and-company-us--nct-nct07900633) - [Emory University: Not applicable (device, behavioral) study closed enrollment, 473 enrolled (HIV Infections, STI)](/report/clinicaltrialstartpulse/emory-university-us--nct-nct06205368-enrollment) - [Enanta Pharmaceuticals, Inc: Phase 3 study in RSV (860 participants)](/report/clinicaltrialstartpulse/enanta-pharmaceuticals-inc-us--nct-nct07908381) - [Encora, Inc.: Observational study in Essential Tremor (1000 participants)](/report/clinicaltrialstartpulse/encora-inc-us--nct-nct07911488) - [Epizyme, Inc.: Phase 3 study closed enrollment, 599 enrolled (Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma)](/report/clinicaltrialstartpulse/epizyme-inc-us--nct-nct04224493-enrollment) - [Ethicon Endo-Surgery: Observational study closed enrollment, 500 enrolled (Gastroesophageal Reflux)](/report/clinicaltrialstartpulse/ethicon-endo-surgery-us--nct-nct04253392-enrollment) - [Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): Observational study closed enrollment, 52966 enrolled (Suicide Mortality)](/report/clinicaltrialstartpulse/eunice-kennedy-shriver-national-institute-of-child-health-us--nct-nct03027440-enrollment) - [EyeBiotech Ltd.: Phase 3 study closed enrollment, 1054 enrolled (Diabetic Macular Edema (DME))](/report/clinicaltrialstartpulse/eyebiotech-ltd-us--nct-nct06957080-enrollment) - [Florida State University: Not applicable (device, behavioral) study in Alcohol Drinking, HIV Infections (360 participants)](/report/clinicaltrialstartpulse/florida-state-university-us--nct-nct07911644) - [Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico: Observational study in Chronic Lung Diseases (683 participants)](/report/clinicaltrialstartpulse/fondazione-irccs-ca-granda-ospedale-maggiore-policlinico-us--nct-nct07874139) - [Fred Hutchinson Cancer Center: Not applicable (device, behavioral) study closed enrollment, 374 enrolled (Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm)](/report/clinicaltrialstartpulse/fred-hutchinson-cancer-center-us--nct-nct05075759-enrollment) - [Geisinger Clinic: Not applicable (device, behavioral) study completed, 51218 enrolled (Influenza, Vaccination)](/report/clinicaltrialstartpulse/geisinger-clinic-us--nct-nct07798882-completed) - [Genentech, Inc.: Phase 4 study completed, 403 enrolled (Spinal Muscular Atrophy)](/report/clinicaltrialstartpulse/genentech-inc-us--nct-nct05232929-completed) - [Genmab: Phase 2 study closed enrollment, 543 enrolled (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma)](/report/clinicaltrialstartpulse/genmab-us--nct-nct04663347-enrollment) - [Genmab: Phase 2 study closed enrollment, 666 enrolled (DLBCL, High-grade B-cell Lymphoma (HGBCL))](/report/clinicaltrialstartpulse/genmab-us--nct-nct03625037-enrollment) - [Genmab: Phase 3 study closed enrollment, 621 enrolled (Head and Neck Squamous Cell Carcinoma)](/report/clinicaltrialstartpulse/genmab-us--nct-nct06496178-enrollment) - [Genmab: Phase 3 study closed enrollment, 699 enrolled (Head and Neck Squamous Cell Carcinoma)](/report/clinicaltrialstartpulse/genmab-us--nct-nct06525220-enrollment) - [Genmab: Phase 3 study started recruiting, 600 planned (Colorectal Cancer)](/report/clinicaltrialstartpulse/genmab-us--nct-nct07775287-recruiting) - [George Washington University: Not applicable (device, behavioral) study started recruiting, 588 planned (Colorectal Cancer)](/report/clinicaltrialstartpulse/george-washington-university-us--nct-nct07220018-recruiting) - [George Washington University: Observational study in Influenza, COVID-19 (550 participants)](/report/clinicaltrialstartpulse/george-washington-university-us--nct-nct07871448) - [H. Lundbeck A/S: Phase 3 study closed enrollment, 401 enrolled (Multiple System Atrophy)](/report/clinicaltrialstartpulse/h-lundbeck-a-s-us--nct-nct06706622-enrollment) - [Harvard School of Public Health (HSPH): Not applicable (device, behavioral) study in Dietary Intakes, Physical Activity (456 participants)](/report/clinicaltrialstartpulse/harvard-school-of-public-health-hsph-us--nct-nct07874295) - [Health Sciences North Research Institute: Phase 4 study completed, 393 enrolled (Elderly Immune System)](/report/clinicaltrialstartpulse/health-sciences-north-research-institute-us--nct-nct02297542-completed) - [HeartFlow, Inc.: Not applicable (device, behavioral) study in CAD - Coronary Artery Disease (500 participants)](/report/clinicaltrialstartpulse/heartflow-inc-us--nct-nct07853716) - [Hoffmann-La Roche: Phase 3 study closed enrollment, 382 enrolled (Cancer)](/report/clinicaltrialstartpulse/hoffmann-la-roche-us--nct-nct03148418-enrollment) - [Hoffmann-La Roche: Phase 3 study closed enrollment, 459 enrolled (Primary IgA Nephropathy)](/report/clinicaltrialstartpulse/hoffmann-la-roche-us--nct-nct05797610-enrollment) - [Hoffmann-La Roche: Phase 3 study closed enrollment, 672 enrolled (Diabetic Macular Edema)](/report/clinicaltrialstartpulse/hoffmann-la-roche-us--nct-nct04108156-enrollment) - [Hoffmann-La Roche: Phase 3 study started recruiting, 400 planned (Non-small Cell Lung Cancer)](/report/clinicaltrialstartpulse/hoffmann-la-roche-us--nct-nct07541170-recruiting) - [Inari Medical: Not applicable (device, behavioral) study completed, 1200 enrolled (Pulmonary Embolism)](/report/clinicaltrialstartpulse/inari-medical-us--nct-nct06055920-completed) - [Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz: Observational study in Tumor Burden, Neuroendocrine (NE) Tumors (400 participants)](/report/clinicaltrialstartpulse/instituto-de-investigacion-sanitaria-de-la-fundacion-us--nct-nct07903532) - [Intra-Cellular Therapies, Inc.: Phase 3 study in Generalized Anxiety Disorder (705 participants)](/report/clinicaltrialstartpulse/intra-cellular-therapies-inc-us--nct-nct07856420) - [Jade Biosciences, Inc.: Phase 3 study in IgA Nephropathy (IgAN) (480 participants)](/report/clinicaltrialstartpulse/jade-biosciences-inc-us--nct-nct07902817) - [Janssen Biotech, Inc.: Observational study closed enrollment, 4970 enrolled (Crohn's Disease, Ulcerative Colitis)](/report/clinicaltrialstartpulse/janssen-biotech-inc-us--nct-nct00606346-enrollment) - [Janssen Biotech, Inc.: Observational study closed enrollment, 535 enrolled (Ulcerative Colitis)](/report/clinicaltrialstartpulse/janssen-biotech-inc-us--nct-nct02808780-enrollment) - [Janssen Pharmaceutica N.V., Belgium: Phase 3 study closed enrollment, 691 enrolled (Prostatic Neoplasms)](/report/clinicaltrialstartpulse/janssen-pharmaceutica-n-v-belgium-us--nct-nct04557059-enrollment) - [Janssen Research & Development, LLC: Phase 1 study closed enrollment, 701 enrolled (Carcinoma, Non-Small-Cell Lung)](/report/clinicaltrialstartpulse/janssen-research-and-development-llc-us--nct-nct04077463-enrollment) - [Janssen Research & Development, LLC: Phase 1 study closed enrollment, 751 enrolled (Non-Small-Cell Lung Cancer)](/report/clinicaltrialstartpulse/janssen-research-and-development-llc-us--nct-nct02609776-enrollment) - [Janssen Research & Development, LLC: Phase 2 study closed enrollment, 333 enrolled (Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma)](/report/clinicaltrialstartpulse/janssen-research-and-development-llc-us--nct-nct05963074-enrollment) - [Janssen Research & Development, LLC: Phase 2 study started recruiting, 440 planned (Asthma)](/report/clinicaltrialstartpulse/janssen-research-and-development-llc-us--nct-nct07746687-recruiting) [1](/hub/clinicaltrialstartpulse/records) [2](/hub/clinicaltrialstartpulse/records/2) [3](/hub/clinicaltrialstartpulse/records/3) 4 [5](/hub/clinicaltrialstartpulse/records/5) [Browse ClinicalTrialStartPulse by category and location](/hub/clinicaltrialstartpulse) · [Search and filter ClinicalTrialStartPulse](/v/clinicaltrialstartpulse)